Academic Medical Research Institute
Academic Medical Research Institute
Los Angeles, California, United States10 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Not yet recruiting | Phase 3 | 2026-10-06 | NCT07861100 | |
| A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, membranous glomerulonephritis, nephritis, urinary system disorder | Recruiting | Phase 3 | 2026-10-01 | NCT07851220 | |
| A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, kidney disorder, urinary system disorder | Recruiting | Phase 3 | 2026-09-30 | NCT06963827 | |
| A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) | Primary Membranous Nephropathy | Recruiting | Phase 3 | 2026-09-29 | NCT06962800 | |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) | Arterial Occlusive Diseases, Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Infarction, Male Urogenital Diseases, Necrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, chronic renal failure syndrome, coronary artery disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, heart disorder, ischemic disease, kidney disorder, kidney failure, metabolic disease, myocardial infarction, myocardial ischemia, peripheral arterial disease, peripheral vascular disease, urinary system disorder, vascular disorder | Recruiting | Phase 2 / Phase 3 | 2026-09-21 | NCT05485961 | |
| A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia | Nutritional and Metabolic Diseases, hyperphosphatemia, metabolic disease, phosphorus metabolism disease | Recruiting | Phase 2 | 2026-08-26 | NCT06712654 | |
| Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease | Chronic Disease, Chronic Kidney Diseases, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, diabetes mellitus, endocrine system disorder, glucose metabolism disease, kidney disorder, kidney failure, metabolic disease, type 2 diabetes mellitus, urinary system disorder | Active, not recruiting | Phase 3 | 2026-08-11 | NCT05099770 | |
| Study of WAL0921 in Patients With Glomerular Kidney Diseases | Diabetes Complications, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, diabetes mellitus, diabetic kidney disease, endocrine system disorder, glomerulonephritis, immune system disorder, kidney disorder, minimal change disease, nephritis, nephrosis, primary focal segmental glomerulosclerosis, urinary system disorder | Recruiting | Phase 2 | 2026-08-03 | NCT06466135 | |
| A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, kidney disorder, nephritis, urinary system disorder | Recruiting | Phase 3 | 2026-06-25 | NCT05696613 | |
| Atrasentan in Patients With Proteinuric Glomerular Diseases | Alport syndrome, Collagen Diseases, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Diabetes Complications, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Skin and Connective Tissue Diseases, Urogenital Abnormalities, Urogenital Diseases, autoimmune disease, connective tissue disorder, diabetes mellitus, diabetic kidney disease, endocrine system disorder, focal segmental glomerulosclerosis, glomerulonephritis, hereditary nephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Active, not recruiting | Phase 2 | 2026-06-01 | NCT04573920 |